Botulinum toxin type A therapy for cervical dystonia.

Area of Science:

• Neurology
• Pharmacology
• Clinical Trials

Background:

• Cervical dystonia is a disabling movement disorder causing involuntary head posturing and pain.
• Botulinum toxin type A (BtA) is a primary treatment for cervical dystonia.
• This review updates evidence on BtA efficacy and safety.

Purpose of the Study:

• To compare the efficacy, safety, and tolerability of BtA versus placebo in individuals with cervical dystonia.
• To analyze outcomes based on BtA dose, formulation, and injection guidance techniques.

Main Methods:

• Systematic review and meta-analysis of double-blind, randomized, placebo-controlled trials (RCTs).
• Included nine RCTs with 1144 participants, assessing cervical dystonia impairment and adverse events.
• Analyzed data using random-effects models, with pre-planned subgroup analyses.

Main Results:

• BtA significantly improved cervical dystonia impairment (mean 8.09 points reduction on TWSTRS) and pain (mean 2.11 points reduction) at four weeks post-injection compared to placebo.
• Participants and clinicians reported subjective improvements, with high confidence in the evidence for tolerability.
• Increased risk of adverse events observed, including neck weakness (14%), dysphagia (11%), and diffuse weakness (8%).

Conclusions:

• BtA treatment provides clinically relevant reductions in cervical dystonia impairment and pain, with high confidence in its tolerability.
• Moderate certainty evidence indicates an increased risk of specific adverse events with BtA.
• Further research is needed on repeated injection cycles, optimal intervals, quality of life impact, and duration of effect.